---

All Mechanisms Producing Sedation in Humans + Drugs Acting via Each

---

1. GABA-A Receptor Positive Allosteric Modulation (Enhanced Cl⁻ Influx)

A. Benzodiazepines

• Mechanism: Bind to the α/γ subunit interface of GABA-A. They increase the frequency of Cl⁻ channel opening (require GABA to be present - they are modulators, not direct agonists).
• Drugs: Diazepam, lorazepam, midazolam, clonazepam, alprazolam, triazolam, temazepam, oxazepam, chlordiazepoxide, flurazepam, nitrazepam, clorazepate
• Reversal agent: Flumazenil (competitive antagonist at the same site)

B. Barbiturates

• Mechanism: Bind to a separate site on GABA-A. They increase the duration of Cl⁻ channel opening. At high doses, they can directly activate the channel (GABA-independent) - this underlies their narrow therapeutic index and lethality in overdose.
• Drugs: Phenobarbital, pentobarbital, secobarbital, amobarbital, butabarbital, thiopental (ultra-short acting), methohexital
• Source: Kaplan & Sadock's Comprehensive Textbook of Psychiatry - barbiturates alter Cl⁻ channel duration of opening vs benzodiazepines' frequency increase

C. Non-benzodiazepine "Z-drugs" (BzRA / GABA-A α1-selective)

• Mechanism: Bind selectively to GABA-A receptors containing the α1 subunit (the subunit primarily mediating sedation). More selective than classical benzodiazepines.
• Drugs: Zolpidem, zaleplon, zopiclone, eszopiclone
• Shared pharmacology with benzodiazepines but relatively less anxiolytic/anticonvulsant effect due to subunit selectivity.

D. Propofol

• Mechanism: Potentiates GABA-A receptor (binds to the β subunit - etomidate produces sedation at β2, anesthesia at β3; propofol acts similarly). Also inhibits NMDA receptors and P/Q-type calcium channels.
• Use: IV sedation and general anesthesia induction/maintenance
• Source: Barash's Clinical Anesthesia, 9e; K.J. Lee's Essential Otolaryngology

E. Etomidate

• Mechanism: GABA-A agonist (β2/β3 subunit) - produces sedation at β2, anesthesia at β3. Also inhibits NMDA receptors.
• Use: IV induction agent; procedural sedation

F. Neurosteroids (Endogenous/Exogenous)

• Mechanism: Positive allosteric modulators of GABA-A at a distinct neurosteroid-binding site (transmembrane domain of β subunit).
• Drugs: Alphaxalone (alfaxalone), brexanolone (allopregnanolone - approved for postpartum depression), ganaxolone

G. Volatile/Inhaled Anesthetics

• Mechanism: Multiple targets including GABA-A potentiation (major), NMDA inhibition, and K⁺ channel (TREK-1) activation. GABA-A enhancement is a primary contributor.
• Drugs: Sevoflurane, isoflurane, desflurane, halothane, nitrous oxide (partial - mainly NMDA), xenon

H. Chloral Hydrate

• Mechanism: Reduced to active metabolite trichloroethanol, which exerts barbiturate-like effects on GABA-A Cl⁻ channel.
• Use: Pediatric procedural sedation, now largely replaced; historically known as "knockout drops"
• Source: Goodman & Gilman's, p. 457

I. Alcohol (Ethanol)

• Mechanism: GABA-A positive modulator (increases Cl⁻ conductance) + NMDA receptor antagonist. Both mechanisms contribute to sedation/intoxication.
• Low doses: GABA-A enhancement dominates (disinhibition/euphoria)
• Higher doses: CNS depression, stupor, coma

J. GHB (Gamma-Hydroxybutyrate)

• Mechanism: GHB receptor agonist (a distinct GPCR) at low concentrations; GABA-B agonist at higher concentrations. Produces profound sedation/coma.
• Clinical use: Sodium oxybate (Xyrem) for narcolepsy with cataplexy
• Source: Katzung's Basic & Clinical Pharmacology, 16e

K. Meprobamate / Carisoprodol

• Mechanism: Meprobamate has benzodiazepine-like properties (modulates GABA-A/GABA-B). Carisoprodol's mechanism is not fully elucidated but it blocks interneuronal activity in the spinal cord; it is metabolized to meprobamate.
• Drugs: Meprobamate (anxiolytic/sedative), carisoprodol (muscle relaxant with sedation)
• Source: Tintinalli's Emergency Medicine; Goodman & Gilman's

---

2. Alpha-2 Adrenergic Receptor Agonism (Locus Coeruleus Inhibition)

• Mechanism: Presynaptic α2 receptors in the locus coeruleus (brain's main noradrenergic nucleus) - agonism decreases norepinephrine release, reducing arousal pathways. Also activates postsynaptic inward-rectifying K⁺ channels, hyperpolarizing neurons. Uniquely produces a sedation resembling natural sleep (non-REM predominant), preserving respiratory drive.
• Drugs:
  • Dexmedetomidine - highly selective α2 agonist (7-8x more potent than clonidine); used for ICU sedation, procedural sedation, awake fiberoptic intubation
  • Clonidine - α2 agonist (less selective); used for hypertension, but causes significant sedation; also used in premedication
  • Tizanidine - α2 agonist used as a muscle relaxant; sedation is a major side effect
  • Guanfacine - α2A selective; sedation noted especially with immediate-release formulation
• Source: Barash's Clinical Anesthesia, 9e; Bradley & Daroff's Neurology

---

3. Histamine H1 Receptor Antagonism

• Mechanism: Histamine via H1 receptors in the hypothalamus (tuberomammillary nucleus) promotes wakefulness. H1 blockade removes this wakefulness drive, causing sedation. Most sedating antihistamines also have anticholinergic activity (muscarinic blockade), which contributes further.
• Drugs:
  • First-generation antihistamines (high CNS penetration - most sedating): Diphenhydramine (Benadryl), promethazine, hydroxyzine, chlorpheniramine, doxylamine, cyproheptadine, trimeprazine, doxepin (also tricyclic), meclizine
  • Second-generation (lower sedation due to lower CNS penetration): Cetirizine (still moderately sedating), loratadine (minimal), fexofenadine (minimal)
  • Antipsychotics with strong H1 blockade (see also below): Quetiapine, olanzapine, clozapine - H1 antagonism accounts for much of their sedation
  • Tricyclic antidepressants: Amitriptyline, doxepin, trimipramine - sedation largely via H1 blockade
• Source: Kaplan & Sadock's Synopsis of Psychiatry - "Activation of H1 receptors stimulates wakefulness; therefore, receptor antagonism causes sedation"

---

4. Dopamine D2 / Multiple Receptor Antagonism (Antipsychotics)

• Mechanism: Sedation from antipsychotics is primarily driven by H1 antagonism (see above) + muscarinic M1 antagonism + α1 adrenergic antagonism (all of which reduce arousal). D2 blockade itself is less directly sedating but reduces mesolimbic activity.
• Drugs (ranked by sedating potential):
  • Most sedating (high H1/α1 affinity): Chlorpromazine, thioridazine, clozapine, quetiapine, olanzapine
  • Moderately sedating: Risperidone, ziprasidone, perphenazine
  • Less sedating: Haloperidol (low H1/muscarinic affinity), aripiprazole
• Source: Stahl's Essential Psychopharmacology

---

5. Orexin (Hypocretin) Receptor Antagonism

• Mechanism: Orexin neurons in the lateral hypothalamus promote and stabilize wakefulness. Blocking orexin-1 and orexin-2 receptors removes the wakefulness-stabilizing signal, allowing the natural sleep pathway to predominate. This is a physiologically driven sedation without significant respiratory depression.
• Drugs:
  • Suvorexant (Belsomra) - dual orexin receptor antagonist (DORA); approved for insomnia
  • Lemborexant (Dayvigo) - DORA; approved for insomnia
  • Daridorexant (Quviviq) - DORA; approved 2022 for insomnia
• Source: Goodman & Gilman's, p. 457; Bradley & Daroff's Neurology

---

6. Melatonin Receptor Agonism (MT1 / MT2)

• Mechanism: Melatonin from the pineal gland acts on MT1 (suppresses SCN firing, promotes sleep) and MT2 (phase-shifting circadian rhythm) receptors. Agonism of these receptors advances the sleep phase and reduces sleep latency. Sedation is mild, physiologic, and non-habit-forming - no respiratory depression.
• Drugs:
  • Ramelteon (Rozerem) - MT1/MT2 agonist; approved for sleep-onset insomnia; significant first-pass metabolism
  • Tasimelteon (Hetlioz) - MT1/MT2 agonist; approved for non-24-hour sleep-wake disorder (in blind patients)
  • Agomelatine - MT1/MT2 agonist + 5-HT2C antagonist; antidepressant with sedating/sleep-promoting properties
  • Melatonin supplements (endogenous hormone; OTC in many countries)
• Source: Goodman & Gilman's table; Washington Manual of Medical Therapeutics

---

7. Serotonin 5-HT2A Antagonism / Mixed Serotonergic Mechanisms

• Mechanism: 5-HT2A receptor stimulation promotes arousal; blockade promotes sedation and improves sleep architecture (increases slow-wave sleep). Some drugs additionally inhibit serotonin reuptake, with sedation primarily from the antagonist component.
• Drugs:
  • Trazodone - 5-HT2A antagonist + weak SERT inhibitor + H1 antagonist; widely used off-label for insomnia at low doses (25-100 mg)
  • Mirtazapine - α2 antagonist (increases NE/5-HT release) + potent H1 and 5-HT2A/5-HT3 antagonist; sedation driven by H1 and 5-HT2A blockade, especially at lower doses
  • Nefazodone - 5-HT2A antagonist + SERT inhibitor
  • Quetiapine, olanzapine, clozapine - also have strong 5-HT2A antagonism in addition to H1/D2 blockade
• Source: Kaplan & Sadock's Synopsis - mirtazapine 5-HT3 blockade and sedation

---

8. Opioid Receptor Agonism (µ-Opioid > κ-Opioid)

• Mechanism: µ-opioid receptors are coupled to Gi/Go proteins; agonism hyperpolarizes neurons via K⁺ channel activation and reduces Ca²⁺ influx, decreasing neuronal firing. Sedation occurs via inhibition of ascending arousal circuits (locus coeruleus, thalamus). Also causes respiratory depression - the primary cause of opioid overdose death.
• Drugs:
  • Strong: Morphine, fentanyl, heroin (diacetylmorphine), oxycodone, hydromorphone, methadone, sufentanil, remifentanil, alfentanil
  • Moderate: Codeine, tramadol (also has SNRI activity), buprenorphine (partial µ-agonist)
  • Mixed κ/µ: Pentazocine, butorphanol, nalbuphine
• Reversal: Naloxone (competitive opioid antagonist)

---

9. NMDA Receptor Antagonism

• Mechanism: NMDA receptors (glutamate-gated ion channels) mediate excitatory neurotransmission. Blocking them depresses CNS activity. At sub-anesthetic doses, produces dissociative sedation rather than true sleep. At higher doses, full anesthesia/unconsciousness.
• Drugs:
  • Ketamine - dissociative anesthetic; blocks NMDA receptors; unique because it produces sedation/anesthesia while often preserving airway reflexes and respiratory drive. Also has emerging antidepressant properties.
  • Phencyclidine (PCP) - NMDA antagonist; high abuse potential, dissociative
  • Nitrous oxide - partial NMDA antagonist; contributes to inhaled anesthetic sedation
  • Dextromethorphan - weak NMDA antagonist; at overdose, dissociative sedation
  • Memantine - NMDA antagonist (Alzheimer's treatment); sedation at higher doses

---

10. Cannabinoid CB1 Receptor Agonism

• Mechanism: CB1 receptors (Gi-coupled) are widely expressed in the brain. Presynaptic CB1 activation reduces release of both excitatory (glutamate) and inhibitory (GABA) neurotransmitters, with net effects that include sedation, relaxation, and at higher doses, somnolence.
• Drugs:
  • THC (tetrahydrocannabinol) - partial CB1 agonist; sedation especially at high doses
  • Nabilone - synthetic cannabinoid; antiemetic with sedation
  • Dronabinol - synthetic THC; sedation noted
  • Nabiximols (Sativex) - THC + CBD combination

---

11. Muscarinic M1 Receptor Antagonism (Anticholinergics)

• Mechanism: Acetylcholine via muscarinic receptors (especially M1) in the basal forebrain promotes wakefulness. Anticholinergic blockade impairs arousal, causing sedation and cognitive blunting. Also disrupts REM sleep.
• Drugs with prominent anticholinergic sedation:
  • Scopolamine (most CNS-penetrant - used as a pre-anesthetic and antiemetic; causes frank sedation/drowsiness)
  • Benztropine, trihexyphenidyl (antiparkinson agents)
  • Tricyclic antidepressants (amitriptyline, imipramine, doxepin) - muscarinic blockade contributes alongside H1 blockade
  • First-gen antihistamines (diphenhydramine, promethazine) - dual H1 + M1 blockade

---

12. Sodium Channel Stabilization / Miscellaneous

• Mechanism: Some anticonvulsants reduce neuronal hyperexcitability by stabilizing Na⁺ channels or enhancing GABA - as a side effect (not primary sedation mechanism), they cause significant drowsiness.
• Drugs:
  • Pregabalin, gabapentin - bind to α2δ subunit of voltage-gated Ca²⁺ channels; reduce excitatory neurotransmitter release; sedation is a major side effect
  • Valproate - multiple mechanisms (Na⁺ channel block, GABA increase, histone deacetylase inhibition); sedation common
  • Carbamazepine, oxcarbazepine - Na⁺ channel blockade; sedation especially early in treatment
  • Lacosamide, lamotrigine - Na⁺ channel effects; variable sedation

---

Summary Table

---

• GABA-A drugs and opioids can cause life-threatening respiratory depression in overdose (GABA reversal: flumazenil; opioid reversal: naloxone)
• Alpha-2 agonists and orexin antagonists cause sedation with minimal respiratory depression - safer in that regard
• Melatonin agonists produce physiologic sedation - non-habit-forming, no dependence
• Ketamine is unique - sedation/anesthesia without respiratory depression (preserves airway reflexes at dissociative doses)
• Barbiturates have a very narrow therapeutic index because they can directly activate GABA-A without GABA; benzodiazepines and Z-drugs cannot exceed the ceiling set by endogenous GABA, making them much safer in overdose